<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995618</url>
  </required_header>
  <id_info>
    <org_study_id>A3006GT</org_study_id>
    <nct_id>NCT00995618</nct_id>
  </id_info>
  <brief_title>Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia</brief_title>
  <official_title>A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Febuxostat Compared With Tranilast Alone and Febuxostat Alone in Healthy Subjects With Hyperuricemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, 3-period crossover phase 2 study in patients with
      documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics
      (PK) and pharmacodynamics (PD) and to evaluate the effect of febuxostat on tranilast PK and
      PD as measured by reduction in serum uric acid levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean decrease in serum uric acid levels</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of pharmacokinetic parameters (AUC, Cmax) of tranilast, febuxostat and combination</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Tranilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranilast tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Febuxostat tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranilast plus febuxostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranilast</intervention_name>
    <description>Tranilast tablets, 300 mg, QD</description>
    <arm_group_label>Tranilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat Tablets, 40 mg, QD</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination - Tranilast and Febuxostat</intervention_name>
    <description>Tranilast, 300 mg QD; Febuxostat, 40 mg QD</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 to 70

          -  Subjects with hyperuricemia who are otherwise healthy

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Known history of gout

          -  Clinically significant infection at Screening

          -  Known sensitivity to tranilast or febuxostat
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Nuon Clinical Trials Group</last_name>
    <role>Study Director</role>
    <affiliation>Nuon Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuon Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuon Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuon Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2009</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nuon Therapeutics Clinical Trials Contact</name_title>
    <organization>Nuon Therapeutics</organization>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Hyperuricemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
    <mesh_term>Tranilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

